Outcomes13

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 13 of 13

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in IGF-1 After 30 Days of Intervention Compared to Baseline Level.	Baseline and after 30 days of intervention	22 Subjects completed both interventions and lab results were available.	ng/ml	MEAN
SECONDARY	Change in Acyl-Ghrelin After 30 Days of Intervention Compared to Baseline Level.	Baseline and after 30 days of intervention.	22 subjects completed both interventions.	pg/ml	MEAN
SECONDARY	Change in Leptin After 30 Days of Intervention Compared to Baseline Level.	Baseline and after 30 days of intervention	22 subjects completed both interventions.	ng/ml	MEAN
SECONDARY	Change in Insulin After 30 Days of Intervention Compared to Baseline Level.	Baseline and after 30 days of intervention	22 subjects completed both interventions.	uIU/ml	MEAN
SECONDARY	Change in Des-Acyl Ghrelin After 30 Days of Intervention Compared to Baseline Level.	Baseline and after 30 days of intervention	22 Subjects completed both interventions.	pg/ml	MEAN
SECONDARY	Change in TNF-alpha After 30 Days of Intervention Compared to Baseline Level.	Baseline and after 30 days of intervention	22 subjects had samples available for the MK-0677 intervention, and 21 samples were available for the placebo intervention.	pg/ml	MEAN
SECONDARY	Change in CRPs After 30 Days of Intervention Compared to Baseline Level.	Baseline and after 30 days of intervention	22 Subjects completed both interventions.	mg/ml	MEAN
SECONDARY	Change in IL-1 After 30 Days of Intervention Compared to Baseline Level.	Baseline and after 30 days of intervention	22 subjects had samples available for the MK-0677 intervention, and 21 samples were available for the placebo intervention.	pg/ml	MEAN
SECONDARY	Changes in the Following Level: IL-6	After the subject has comleted their last visit	22 subjects had samples available for the MK-0677 intervention, and 21 samples were available for the placebo intervention.	pg/mL	MEAN
SECONDARY	Change in IL-10 After 30 Days of Intervention Compared to Baseline Level.	Baseline and after 30 days of intervention	22 subjects had samples available for the MK-0677 intervention, and 21 samples were available for the placebo intervention.	pg/ml	MEAN
SECONDARY	Change in Esterase After 30 Days of Intervention Compared to Baseline Level.	Baseline and after 30 days of intervention	22 subjects completed both interventions and results were available.	units/ml	MEAN
SECONDARY	Change in Adiponectin After 30 Days of Intervention Compared to Baseline Level.	Baseline and after 30 days of intervention	22 subjects had samples available for the MK-0677 intervention, and 21 samples were available for the placebo intervention.	ng/ml	MEAN
SECONDARY	Change in Ghrelin After 30 Days of Intervention Compared to Baseline Level.	Baseline and after 30 days of intervention	22 subjects completed both interventions and lab results were available for all 22.	pg/ml	MEAN

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00395291/outcomes

API reference For AI assistants